Abstract:The development of a preventative HIV vaccine able to elicit broadly neutralizing antibodies (bNAbs) remains a major challenge. Antibodies that recognize the V2 region at the apex of the HIV envelope trimer are among the most common bNAb specificities during chronic infection and many exhibit remarkable breadth and potency. Understanding the developmental pathway of these antibodies has provided insights into their precursors, and the viral strains that engage them, as well as defined how such antibodies mature to acquire breadth. V2‐apex bNAbs are derived from rare precursors with long anionic CDR H3s that are often deleted in the B cell repertoire. However, longitudinal studies suggest that once engaged, these precursors contain many of the structural elements required for neutralization, and can rapidly acquire breadth through moderate levels of somatic hypermutation in response to emerging viral variants. These commonalities in the precursors and mechanism of neutralization have enabled the identification of viral strains that show enhanced reactivity for V2 precursors from multiple donors, and may form the basis of germline targeting approaches. In parallel, new structural insights into the HIV trimer, the target of these quaternary antibodies, has created invaluable new opportunities for ontogeny‐based immunogens designed to select for rare V2‐bNAb precursors, and drive them toward breadth.

Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction

Targeted selection of HIV-specific antibody mutations by engineering B cell maturation

Designing boosting immunogens for HIV-1 vaccine development

A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses

Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development

Vaccination Induces Maturation of Diverse Unmutated VRC01-class Precursors to HIV-1 Broadly Neutralizing Antibodies in an Ig-humanized Mouse Model

Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth

Vaccination induces broadly neutralizing antibody precursors to HIV gp41

Heterologous prime-boost vaccination drives early maturation of HIV broadly neutralizing antibody precursors in humanized mice

A vaccine strategy for inducing broadly neutralizing antibodies against HIV

Vaccine induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques

Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site

mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies

Membrane-bound mRNA immunogens lower the threshold to activate HIV Env V2 apex-directed broadly neutralizing B cell precursors in humanized mice

Vaccination induces HIV broadly neutralizing antibody precursors in humans

Ontogeny‐based immunogens for the induction of V2‐directed HIV broadly neutralizing antibodies

Vaccine priming of rare HIV broadly neutralizing antibody precursors in nonhuman primates

HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen

Autoreactivity and Broad Neutralization of Antibodies Against HIV-1 Are Governed by Distinct Mutations: Implications for Vaccine Design Strategies

Augmenting Neutralization Breadth Against Diverse HIV-1 by Increasing the Ab-Ag Interface on V2

mRNA-LNP prime boost evolves precursors toward VRC01-like broadly neutralizing antibodies in preclinical humanized mouse models